Debuts at the NY20 Foundation for Podiatric Medicine Meeting

HACKENSACK, N.J.,January 21, 2020 RoyalBiologics, an ortho-biologics company specializing inthe research and advancement of novel ortho-biologics solutions, todayannounced the launch of Cryo-Cord, the first DMSO-free viable umbilical cord graft.The company will be showcasing Cryo-Cord along with its new portfolio ofAutologous Live Cellular (ALC) technologies at the NY20 Foundation forPodiatric Medicine meeting, held January 24-26 in New York, NY for more than1500 clinical attendees.

The companywill feature its full suite of surgical biologic offerings at exhibit booth #322,and on the podium for Innovation Theater presentations at 10:30am on Friday1/24/20 and 12pm on Saturday 1/25/20. Thesescientific presentations will feature several products within the RoyalBiologics portfolio. At its booth, RoyalBiologics will showcase its comprehensive ALC portfolio designed to personalizelive regenerative healing for a wide variety of wound types across theorthopedics continuum.

The launch of Cryo-Cordenablesproviders with the first DMSO-free viableumbilical cord tissue. Cryo-Cord hasbeen obtained with consent from healthy mothers during cesarean sectiondelivery and is intended for use as a soft tissue barrier or wound dressing. Cryo-Cord is processed using aseptic techniques and frozenwith a proprietary cryoprotectant.

Cryo-cord offers a new enhancement to traditional wound caretherapies and we are excited to pave the way with the first DMSO-freecryoprotectant graft on the market, said Salvatore Leo, Chief ExecutiveOfficer of Royal Biologics.

Other featuredproducts at NY20 will include Maxx-Cell, which was launched as the worlds mostadvanced bone marrow aspiration device. Maxx-Celloffers a new technique to a gold standard approach of aspirating a patientsautologous bone marrow cells. Maxx-Cell however does not requirecentrifugation to deliver a final end product. The Maxx-Cell system maximizesstem and progenitor cell yields by giving the surgeon the ability toefficiently harvest bone marrow from multiple levels within the medullaryspace, while restricting dilution of peripheral blood. As a result, Maxx-Celldelivers a high, most pure enriched form of bone marrow aspirate without theneed for centrifugation.

This month, the company has alsoannounced the launch of MAGNUS, which is a DMSO-free viable cellular boneallograft and demos will be available during the conference. MAGNUS presents aunique solution to traditional viable cellular allograft technology as itutilizes a DMSO-free cryoprotectant. This novel approach to the viable cellularallograft market differentiates MAGNUS from other technologies currently available.

Leo added, We are excited to participatein NY20 and share how our Autologous Live Cellular based therapies give thesurgeons an efficient and effective way to enhance surgical outcomes by providingalternatives to conventional therapies for bone and soft tissue relatedinjuries. We also believe that in a cost-conscious industry, we can provide novelviable cellular products that provide value at the point of care.

Towatch the latest ALC product videos and learn more about the range ofregenerative medical products offered by Royal Biologics, along with a scheduleof 2020 conferences, visit http://www.RoyalBiologics.com.

About Royal Biologics

Royal Biologics is an orthobiologicscompany specializing in the research and advancement of Regenerative CellularTherapy. Its primary focus is on usingautologous bioactive cells to help promote healing in a wide range of clinicalsettings, with its portfolio of FDA-approved medical devices. For more information on its line of products,visit http://www.royalbiologics.com.

For more mediainformation, contact:

Lisa Hendrickson,LCH Communications

lisa@lchcommunications.com

516-767-8390

Read more here:
Royal Biologics Announces The Launch of CRYO-CORD The First NON-DMSO Viable Umbilical Cord Graft - OrthoSpineNews